Need help now? Free crisis lines and helplines, worldwide — chapter 02 →
0 results for

Neurodiversity — ADHD, Autism, Dyslexia, Dyspraxia, Dyscalculia & Tics

Category 13 of 20 in chapter 17, The Research Behind It, of Notbroken's Free Metabolic & Mental Health Help Directory: 13 listings, each carefully picked (listed, not endorsed). All 280 listings in The Research Behind It · Open the full directory of 2299 listings.
13
Listings
13 / 20
Category
17 / 18
Chapter
Latest Edition Always download the most up-to-date version, free, at notbroken.io
Know someone who could benefit? Share this guide with them.
Free to use · No account needed
Navigation
Contents
17
The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows
THE EVIDENCE
THE EVIDENCE

The Research Behind It — Free Papers on Chronic Disease and What the Evidence Shows

Why would a support group, a walking club, a low-carb book or an online CBT course help — and what drives chronic illness in the first place? This chapter gathers the research behind each part of the directory, and the research on causes: metabolic therapies, the nutrients in food, plastics and pollution, stress and trauma, the microbiome, and damp and mould. That is 280 studies, reviews and clinical guidelines, every one free to read and download in full, permanently and without a login. Most are kept in PubMed Central, the US National Library of Medicine's public archive; the rest are open access at the publisher, or free guidance from the World Health Organization and NICE. Each entry says what was found, why it matters here — which listings it backs up, or what it explains about chronic disease — and how strong the evidence is: strong (systematic reviews and guidelines with consistent findings), moderate (smaller or lower-certainty reviews, single large trials and large cohort studies) or early (pilot, cross-sectional and laboratory studies — promising, not proof). Studies that follow people over time show links, not proof of cause, and the entries say so. Where a study was funded by a company, or its authors run a listed programme, the note says so; where a listed book or service was not itself tested, the entry says it backs the approach rather than the product. Research moves on, so read these as good reasons to try something, not guarantees — and talk to your own clinician before changing a treatment or a medicine. Every paper was checked at least twice: by the researcher who chose it and again, independently, against its abstract and full text (the first 186 a third time); its public record was checked for corrections, retractions and expressions of concern (none is retracted), every number was looked up in the full text, and every link was opened in a browser.

Neurodiversity — ADHD, Autism, Dyslexia, Dyspraxia, Dyscalculia & Tics

Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis — Cortese et al., Lancet Psychiatry 2018

Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis). Strong evidence. Lancet Psychiatry 2018;5(9):727–738. DOI 10.1016/S2215-0366(18)30269-4. Free full text in PubMed Central (PMC6109107) — open access, CC BY 4.0. Note: Trials were short (about 12 weeks), with too few data to judge effects at 6–12 months, and the authors rated certainty low or very low for many comparisons.
What It Found
Pooled 133 double-blind trials of seven ADHD medicines. Over about 12 weeks, all seven reduced clinician-rated ADHD symptoms in children and adolescents compared with placebo (methylphenidate SMD −0.78, 95% CI −0.93 to −0.62), and four of the five tested in adults did (amphetamines SMD −0.79, −0.99 to −0.58). Weighing benefit against side-effects, the authors favoured methylphenidate for children and amphetamines for adults as first choices for short-term treatment.
Why It Matters Here
Backs up the ADHD practitioner directories and organisations in chapter 09 (CHADD, ADDA, AADPA, ADHD UK) and the ADHD books and webinars in chapter 10 that explain medication choices: a specialist assessment opens the door to medicines with well-tested short-term benefit.
Systematic review and network meta-analysis — 133 double-blind randomised trials (10,068 children and adolescents, 8,131 adults in the main analysis). Strong evidence. Lancet Psychiatry 2018;5(9):727–738. DOI 10.1016/S2215-0366(18)30269-4. Free full text in PubMed Central (PMC6109107) — open access, CC BY 4.0. Note: Trials were short (about 12 weeks), with too few data to judge effects at 6–12 months, and the authors rated certainty low or very low for many comparisons.

Cognitive Behavioral Therapy vs Relaxation With Educational Support for Medication-Treated Adults With ADHD and Persistent Symptoms: A Randomized Controlled Trial — Safren et al., JAMA 2010

Randomised controlled trial — 86 adults with ADHD already taking medication; 12 individual sessions; follow-up to 12 months. Moderate evidence. JAMA 2010;304(8):875–880. DOI 10.1001/jama.2010.1192. Free full text in PubMed Central (PMC3641654). Note: A single-site trial of 86 adults who were already on medication; results may not carry over to unmedicated adults or routine services.
What It Found
Tested the 12-session CBT programme set out in the authors' 'Mastering Your Adult ADHD' manuals in 86 adults whose symptoms persisted despite medication, against relaxation training with education. More people responded to CBT (53% vs 23% on clinician global ratings; 67% vs 33% on an ADHD rating scale), self-reported symptoms also fell more, and those who responded or partly responded to CBT kept their gains at 6 and 12 months.
Why It Matters Here
Backs up 'Mastering Your Adult ADHD' in chapter 10 directly (the trial used the first-edition programme), the ADHD psychologists and therapists found through the chapter 09 directories (ADDA, AADPA, CHADD) and the therapist directories in chapter 05: structured CBT skills can add to medication for adults.
Randomised controlled trial — 86 adults with ADHD already taking medication; 12 individual sessions; follow-up to 12 months. Moderate evidence. JAMA 2010;304(8):875–880. DOI 10.1001/jama.2010.1192. Free full text in PubMed Central (PMC3641654). Note: A single-site trial of 86 adults who were already on medication; results may not carry over to unmedicated adults or routine services.

Autism intervention meta-analysis of early childhood studies (Project AIM): updated systematic review and secondary analysis — Sandbank et al., BMJ 2023

Systematic review and meta-analysis — 252 studies (173 randomised; 289 reports) of young autistic children (average age under 8), 13,304 participants. Moderate evidence. BMJ 2023;383:e076733. DOI 10.1136/bmj-2023-076733. Free full text in PubMed Central (PMC10644209) — open access, CC BY-NC 4.0. Note: Most outcomes were at risk of bias (unblinded raters, caregiver reports); only one effect survived every bias check, and adverse events were seldom reported.
What It Found
Reviewed 252 studies of non-drug early support for young autistic children. In randomised trials, naturalistic developmental behavioural interventions (child-led, play-based) improved social communication (g 0.35, 95% CI 0.23 to 0.47), as did developmental approaches (g 0.28). Most effects lost significance in stricter analyses (no caregiver ratings, blinded assessors); harms were rarely monitored, so the authors say families should watch for distress or negative effects.
Why It Matters Here
Backs up the autism service directories and organisations in chapter 09 that families use to find early support (National Autistic Society directory, Autism Society, Autism-Europe): it shows which early supports have some trial evidence, how modest it is, and why to watch for harms.
Systematic review and meta-analysis — 252 studies (173 randomised; 289 reports) of young autistic children (average age under 8), 13,304 participants. Moderate evidence. BMJ 2023;383:e076733. DOI 10.1136/bmj-2023-076733. Free full text in PubMed Central (PMC10644209) — open access, CC BY-NC 4.0. Note: Most outcomes were at risk of bias (unblinded raters, caregiver reports); only one effect survived every bias check, and adverse events were seldom reported.

Risk markers for suicidality in autistic adults — Cassidy et al., Mol Autism 2018

Cross-sectional survey — 164 autistic adults and 169 general-population adults. Early evidence. Mol Autism 2018;9:42. DOI 10.1186/s13229-018-0226-4. Free full text in PubMed Central (PMC6069847) — open access, CC BY 4.0. Note: A one-off survey of volunteers (self-reported diagnoses, no intellectual disability): it shows associations, not cause and effect.
What It Found
Surveyed 164 autistic and 169 general-population adults. 72% of autistic adults scored at or above the clinical cut-off on a questionnaire about suicidal thoughts and behaviour, against 34% of the comparison group. Among autistic adults, camouflaging (hiding autistic traits to fit in), non-suicidal self-injury and unmet support needs each predicted higher scores after allowing for depression, anxiety and other factors, but each explained only a small extra share (3–4%).
Why It Matters Here
Backs up the autistic-led organisations and communities in chapter 09 (ASAN, Reframing Autism, Wrong Planet) and 'Unmasking Autism' and the AASPIRE toolkit in chapter 10: lowering the pressure to mask and meeting support needs are plausible protective targets.
Cross-sectional survey — 164 autistic adults and 169 general-population adults. Early evidence. Mol Autism 2018;9:42. DOI 10.1186/s13229-018-0226-4. Free full text in PubMed Central (PMC6069847) — open access, CC BY 4.0. Note: A one-off survey of volunteers (self-reported diagnoses, no intellectual disability): it shows associations, not cause and effect.

Experiences of Autism Acceptance and Mental Health in Autistic Adults — Cage et al., J Autism Dev Disord 2018

Cross-sectional online survey — 111 autistic adults (UK). Early evidence. J Autism Dev Disord 2018;48(2):473–484. DOI 10.1007/s10803-017-3342-7. Free full text in PubMed Central (PMC5807490) — open access, CC BY 4.0. Note: A small, self-selected, mostly female online survey using new single-item acceptance ratings; it shows associations, not cause and effect.
What It Found
Surveyed 111 autistic adults in the UK about how far they felt accepted by society, by family and friends, and by themselves. Feeling accepted by others and accepting oneself both predicted lower depression; adding acceptance raised the explained variation in depression from 34.6% to 52.1%. Acceptance by others was also linked to lower stress, but acceptance did not predict anxiety. The 27 people who mentioned camouflaging reported more depression and felt less accepted.
Why It Matters Here
Backs up the autistic-led and neurodiversity-affirming organisations, communities and practitioner directories in chapter 09 (ASAN, Reframing Autism, Neurodivergent Practitioners) and 'Unmasking Autism' in chapter 10: feeling accepted, and accepting oneself, go with better mental health.
Cross-sectional online survey — 111 autistic adults (UK). Early evidence. J Autism Dev Disord 2018;48(2):473–484. DOI 10.1007/s10803-017-3342-7. Free full text in PubMed Central (PMC5807490) — open access, CC BY 4.0. Note: A small, self-selected, mostly female online survey using new single-item acceptance ratings; it shows associations, not cause and effect.

The Development and Evaluation of an Online Healthcare Toolkit for Autistic Adults and their Primary Care Providers — Nicolaidis et al., J Gen Intern Med 2016

Community-based participatory development and single-group pre/post evaluation — 259 autistic adults and 51 primary care providers in all (evaluation: 170 adults, 41 providers). Early evidence. J Gen Intern Med 2016;31(10):1180–1189. DOI 10.1007/s11606-016-3763-6. Free full text in PubMed Central (PMC5023610). Note: No control group, a one-month follow-up and a self-selected US sample, so the improvements cannot be firmly credited to the toolkit.
What It Found
Autistic adults and researchers built the AASPIRE Healthcare Toolkit as equal partners; 259 autistic adults and 51 primary care providers helped develop and test it. Over 94% of autistic users found it easy to use, important and useful; 82% of responding providers rated its accommodations report useful. A month later, average barriers to care fell from 4.07 to 2.82, with small gains in healthcare self-efficacy and, for those who saw their provider, communication satisfaction.
Why It Matters Here
Backs up the AASPIRE Healthcare Toolkit in chapter 10 directly, and the autistic-led organisations and neurodiversity-affirming practitioner directories in chapter 09 that help people ask for healthcare adjustments.
Community-based participatory development and single-group pre/post evaluation — 259 autistic adults and 51 primary care providers in all (evaluation: 170 adults, 41 providers). Early evidence. J Gen Intern Med 2016;31(10):1180–1189. DOI 10.1007/s11606-016-3763-6. Free full text in PubMed Central (PMC5023610). Note: No control group, a one-month follow-up and a self-selected US sample, so the improvements cannot be firmly credited to the toolkit.

Effectiveness of Treatment Approaches for Children and Adolescents with Reading Disabilities: A Meta-Analysis of Randomized Controlled Trials — Galuschka et al., PLoS ONE 2014

Meta-analysis of 22 randomised controlled trials (49 comparisons; 1,138 children in intervention and 764 in control groups). Moderate evidence. PLoS ONE 2014;9(2):e89900. DOI 10.1371/journal.pone.0089900. Free full text in PubMed Central (PMC3935956) — open access, CC BY. Note: The phonics effect was small, shrank further after allowing for likely publication bias, and few trials blinded their assessors.
What It Found
Pooled 22 randomised trials of help for children and teenagers with reading disabilities (dyslexia). Systematic phonics instruction, explicitly teaching letter–sound links and how to blend them, was the only approach with a statistically confirmed benefit for reading and spelling (reading g′ 0.32, 95% CI 0.18 to 0.47). Other approaches tested, such as reading-fluency training, auditory training and coloured overlays, did not show significant effects.
Why It Matters Here
Backs up the dyslexia tutor and assessor directories in chapter 09 (British Dyslexia Association, PATOSS, International Dyslexia Association) and 'Overcoming Dyslexia' in chapter 10, which explains dyslexia as a difficulty with the sounds of words: structured, phonics-based teaching is the approach with trial evidence.
Meta-analysis of 22 randomised controlled trials (49 comparisons; 1,138 children in intervention and 764 in control groups). Moderate evidence. PLoS ONE 2014;9(2):e89900. DOI 10.1371/journal.pone.0089900. Free full text in PubMed Central (PMC3935956) — open access, CC BY. Note: The phonics effect was small, shrank further after allowing for likely publication bias, and few trials blinded their assessors.

International clinical practice recommendations on the definition, diagnosis, assessment, intervention, and psychosocial aspects of developmental coordination disorder — Blank et al., Dev Med Child Neurol 2019

International clinical practice recommendations (European Academy of Childhood Disability) — literature reviews plus formal expert consensus (Delphi). Moderate evidence. Dev Med Child Neurol 2019;61(3):242–285. DOI 10.1111/dmcn.14132. Free full text in PubMed Central (PMC6850610) — open access, CC BY-NC-ND 4.0. Note: Only 8 of the 35 recommendations rest directly on research evidence (the rest are expert consensus), and the authors set them to be revised by the end of 2022.
What It Found
An international panel convened by the European Academy of Childhood Disability agreed 35 recommendations on defining, diagnosing, assessing and treating developmental coordination disorder (dyspraxia), including the first international advice for adolescents and adults. Its top grade (level A) goes to activity- and participation-oriented therapy such as task-specific training or the CO-OP approach; sensory integration therapy is not recommended (evidence inconclusive).
Why It Matters Here
Backs up the dyspraxia/DCD organisations and support groups in chapter 09 (Dyspraxia Foundation, CanChild, DCD Australia, EACD) and 'Caged in Chaos' in chapter 10: DCD is a recognised condition, in adults as well as children, with agreed assessment and therapy pathways.
International clinical practice recommendations (European Academy of Childhood Disability) — literature reviews plus formal expert consensus (Delphi). Moderate evidence. Dev Med Child Neurol 2019;61(3):242–285. DOI 10.1111/dmcn.14132. Free full text in PubMed Central (PMC6850610) — open access, CC BY-NC-ND 4.0. Note: Only 8 of the 35 recommendations rest directly on research evidence (the rest are expert consensus), and the authors set them to be revised by the end of 2022.

The Diagnosis and Treatment of Dyscalculia — Haberstroh & Schulte-Körne, Dtsch Arztebl Int 2019

Systematic review and meta-analysis underpinning the German S3 clinical practice guideline (20 professional societies). Moderate evidence. Dtsch Arztebl Int 2019;116(7):107–114. DOI 10.3238/arztebl.2019.0107. Free full text in PubMed Central (PMC6440373). Note: High-quality trials are few, and there is little evidence or suitable programmes for older teenagers and adults.
What It Found
Summarises the German evidence-based (S3) guideline on dyscalculia, agreed by 20 professional societies and built on a systematic review and meta-analysis. Across intervention studies, maths support had a moderate average effect (g 0.52, 95% CI 0.42 to 0.62). Training aimed at the specific maths content a child finds hard worked best; group sessions were less effective than one-to-one, and the authors advise starting early in primary school with trained specialists.
Why It Matters Here
Backs up the dyscalculia assessor and tutor directories in chapter 09 (Dyscalculia Network, BDA dyscalculia accreditation) and the content-focused teaching approach of 'The Dyscalculia Toolkit' in chapter 10: specialist, individual, content-focused teaching has the best evidence.
Systematic review and meta-analysis underpinning the German S3 clinical practice guideline (20 professional societies). Moderate evidence. Dtsch Arztebl Int 2019;116(7):107–114. DOI 10.3238/arztebl.2019.0107. Free full text in PubMed Central (PMC6440373). Note: High-quality trials are few, and there is little evidence or suitable programmes for older teenagers and adults.

European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part II: psychological interventions — Andrén et al., Eur Child Adolesc Psychiatry 2022

Clinical practice guideline (European Society for the Study of Tourette Syndrome) — systematic literature search to May 2021, narrative review and expert consensus. Strong evidence. Eur Child Adolesc Psychiatry 2022;31(3):403–423. DOI 10.1007/s00787-021-01845-z. Free full text in PubMed Central (PMC8314030) — open access, CC BY 4.0. Note: Exposure and response prevention rests on one randomised trial and group or internet formats on a few small studies; even for HRT/CBIT, effects were medium-sized.
What It Found
The European Society for the Study of Tourette Syndrome's updated guideline on psychological treatment. It advises psychoeducation for everyone first, then behavioural therapy as first-line treatment for children and adults whose tics need it: habit reversal training (HRT, the core of CBIT) or exposure and response prevention. HRT/CBIT has the strongest evidence; cognitive and third-wave therapies are not advised on their own.
Why It Matters Here
Backs up the Tourette organisations and provider directories in chapter 09 (Tourette Association of America, Tourettes Action, Tourette Canada), which offer psychoeducation and routes to behavioural therapy, and the CBIT workbook 'Managing Tourette Syndrome' in chapter 10.
Clinical practice guideline (European Society for the Study of Tourette Syndrome) — systematic literature search to May 2021, narrative review and expert consensus. Strong evidence. Eur Child Adolesc Psychiatry 2022;31(3):403–423. DOI 10.1007/s00787-021-01845-z. Free full text in PubMed Central (PMC8314030) — open access, CC BY 4.0. Note: Exposure and response prevention rests on one randomised trial and group or internet formats on a few small studies; even for HRT/CBIT, effects were medium-sized.

Autistic peer-to-peer information transfer is highly effective — Crompton et al., Autism 2020

Experimental study (diffusion-chain design) — 72 adults in autistic, non-autistic and mixed chains. Early evidence. Autism 2020;24(7):1704–1712. DOI 10.1177/1362361320919286. Free full text in PubMed Central (PMC7545656) — open access, CC BY-NC 4.0. Note: A small laboratory experiment with one storytelling task, in which participants knew each other's diagnosis; it does not measure therapy or support outcomes.
What It Found
72 adults passed a story along chains of eight people that were all autistic, all non-autistic, or mixed. Autistic chains passed on details as well as non-autistic chains did; detail was lost faster only in mixed chains, where people also rated rapport lower. The authors read this as a mismatch between autistic and non-autistic communication styles (the 'double empathy' idea) rather than an autistic deficit.
Why It Matters Here
Backs up the neurodivergent-led practitioner directories in chapter 09 (Neurodivergent Practitioners, Neurodivergent Therapists) and autistic peer communities such as Wrong Planet: autistic people can share information and build rapport with each other as well as non-autistic people do.
Experimental study (diffusion-chain design) — 72 adults in autistic, non-autistic and mixed chains. Early evidence. Autism 2020;24(7):1704–1712. DOI 10.1177/1362361320919286. Free full text in PubMed Central (PMC7545656) — open access, CC BY-NC 4.0. Note: A small laboratory experiment with one storytelling task, in which participants knew each other's diagnosis; it does not measure therapy or support outcomes.

Attention deficit hyperactivity disorder: diagnosis and management (NICE guideline NG87) — NICE 2018

National clinical guideline based on systematic evidence reviews and committee consensus. Strong evidence. NICE NG87, published 14 March 2018, last updated 13 September 2019. Free to read on the NICE website. Note: Written for the NHS in England; services, waiting times and medicine approvals differ in other countries.
What It Found
England's guideline on recognising, diagnosing and supporting ADHD in children, young people and adults. Diagnosis should be made by a specialist with ADHD training. It recommends adjustments to the person's surroundings first, ADHD-focused group parent training for children under 5, medication when symptoms still cause significant problems, and psychological support for adults who prefer not to take medication or still struggle on it.
Why It Matters Here
Backs up the ADHD practitioner directories in chapter 09 (diagnosis by a clinician with ADHD expertise), the ADHD organisations and support groups there (NICE advises telling people about them) and the ADHD information and CBT books in chapter 10. Relevant to people seeking an ADHD assessment and to families.
National clinical guideline based on systematic evidence reviews and committee consensus. Strong evidence. NICE NG87, published 14 March 2018, last updated 13 September 2019. Free to read on the NICE website. Note: Written for the NHS in England; services, waiting times and medicine approvals differ in other countries.

The World Federation of ADHD International Consensus Statement: 208 Evidence-based Conclusions about the Disorder — Faraone et al., Neurosci Biobehav Rev 2021

International consensus statement built only from meta-analyses or studies of 2,000+ people. Strong evidence. Neurosci Biobehav Rev 2021;128:789–818. DOI 10.1016/j.neubiorev.2021.01.022. Free full text in PubMed Central (PMC8328933) — open access, CC BY. Note: A summary of existing evidence rather than new research or a treatment guideline; several authors report links with ADHD medicine makers, as disclosed in the paper.
What It Found
To counter misconceptions that stigmatise ADHD and delay treatment, the authors kept only strong evidence (large studies and meta-analyses that checked for publication bias) and turned it into 208 statements about how common ADHD is, its causes, course, outcomes and treatments. The statements were approved by 80 authors from 27 countries and endorsed by 403 more readers.
Why It Matters Here
Backs up the ADHD organisations and advocacy groups in chapter 09 and the ADHD books in chapter 10: it is a well-sourced reference for explaining that ADHD is a real, treatable condition across the lifespan.
International consensus statement built only from meta-analyses or studies of 2,000+ people. Strong evidence. Neurosci Biobehav Rev 2021;128:789–818. DOI 10.1016/j.neubiorev.2021.01.022. Free full text in PubMed Central (PMC8328933) — open access, CC BY. Note: A summary of existing evidence rather than new research or a treatment guideline; several authors report links with ADHD medicine makers, as disclosed in the paper.
Important Disclaimer
This directory is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making changes to your medication regimen or starting any new therapy.

This document does not guarantee the legitimacy, quality, or suitability of any business, organization, or practitioner listed within. The inclusion of any listing does not constitute an endorsement, recommendation, or verification of credentials. All organizations listed are independent entities over which the creators of this directory have no control or oversight.

This directory is intended to be used as a starting point and reference for the reader to conduct their own research, exercise their own judgment, and apply their own discretion before engaging with any listed organization or professional. Readers are strongly encouraged to independently verify credentials, read reviews, check licensing, and confirm current pricing and availability directly with each organization before committing to any services.

Costs, availability, contact details, and services may change at any time without notice. Information was accurate to the best of our knowledge at the time of publication.

About Notbroken.io: this directory and the accompanying Breathe, Calm, Sleep, Move, Eat, Track and Build tools were created by Nathan Leary, who runs and updates them. How each tool works, its safety notes, the privacy policy and terms of use are at notbroken.io/about, notbroken.io/privacy and notbroken.io/terms. The tools are general wellness aids, not medical devices, and Track is a personal journal that never gives medication advice.

If you are in crisis: Please contact your local emergency services immediately, or reach out to one of the following helplines:

International: Chapter 02 of this directory lists free helplines by situation and country; elsewhere use Find A Helpline — findahelpline.com
United States: 988 Suicide & Crisis Lifeline (call or text 988) • Crisis Text Line (text HOME to 741741)
United Kingdom: Samaritans — 116 123 (free, 24/7)
Canada: Talk Suicide Canada — 988 (call or text, 24/7)
Australia: Lifeline — 13 11 14 (24/7) • Beyond Blue — 1300 22 4636
New Zealand: Need to Talk? — 1737 (free, 24/7)
Europe: European Emergency Number — 112
India: iCall — 9152987821 • Vandrevala Foundation — 1860 2662 345
Singapore: Samaritans of Singapore — 1-767 (24/7)
Japan: TELL Lifeline — 03-5774-0992

No matches found

Nothing matched . Try broadening your search — remove a filter, use a single keyword, describe what you need in a sentence, or browse by a condition, a place, or a type of support.

Suggest a resource